Please login to the form below

Not currently logged in
Email:
Password:

Samsung BioLogics

This page shows the latest Samsung BioLogics news and features for those working in and with pharma, biotech and healthcare.

Biogen launches Remicade biosimilar in the UK

Biogen launches Remicade biosimilar in the UK

Developed by Samsung Bioepis - a joint venture between Biogen and Samsung BioLogics - and marketed in the EU by Biogen, Flixabi (infliximab) won EU marketing authorisation in May this year.

Latest news

  • Second Remicade biosimilar given green light in Europe Second Remicade biosimilar given green light in Europe

    Samsung Bioepis’ Flixabi provides another lower-cost treatment option. Samsung Bioepis has been given EU approval for Flixabi, their biosimilar version of Johnson &Johnson's immunology blockbuster Remicade. ... year. It has been developed by Samsung

  • UCB to sell Biogen Idec’s MS drugs in Asia UCB to sell Biogen Idec’s MS drugs in Asia

    US-based Biogen Idec's previosu experience in the Asian market includes a biosimialrs joint venture with Korea's Samsung Biologics known as Samsung Bioepis.

  • Biogen Idec licenses anti-TNF biosimilars Biogen Idec licenses anti-TNF biosimilars

    Treatment prospects emerge from joint venture with Samsung Biologics.  . Biogen Idec says it has licensed multiple biosimilars of anti-tumour necrosis factor (TNF) developed at its joint venture with Korea's ... Samsung Biologics.

  • Roche signs biologics partnership with Samsung Roche signs biologics partnership with Samsung

    Swiss pharma company Roche has signed a biologics manufacturing deal with Samsung BioLogics. ... Tae-Han Kim, president and CEO of Samsung BioLogics, said: "We are pleased to announce this strategic manufacturing relationship with Roche and look forward

  • BMS signs 10-year biologic manufacturing deal with Samsung BMS signs 10-year biologic manufacturing deal with Samsung

    Agreement covers one of the pharma company's antibody cancer drugs. Bristol-Myers Squibb (BMS) has signed a long-term agreement with Samsung BioLogics that will see the Korean firm manufacture ... Tae-Han Kim, president and CEO of Samsung BioLogics, said:

More from news
Approximately 2 fully matching, plus 5 partially matching documents found.

Latest Intelligence

  • Pharma deals during July 2012 Pharma deals during July 2012

    Two weeks prior to the announcement of the collaboration between Amgen and Watson, Biogen Idec and Samsung Biologics announced the establishment of a $300m joint venture to develop and commercialise biosimilars.

More from intelligence
Approximately 0 fully matching, plus 1 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
GCI Health

GCI Health London is a young, vibrant powerhouse in the European industry with a mission to redefine healthcare communications, starting...

Latest intelligence

The new UK government-pharma industry pricing agreement – welcome news, but there are lessons to be learnt
...
The UK’s new five-year pricing agreement
Pharma has agreed to capped growth again – in exchange for uptake promises...
Digital applications are transforming the market access landscape
Organisations are leveraging new technology to implement a wider range of business models and, in essence, drive market access success by working smarter, faster and with greater economy....

Infographics